Journal article

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

Ester Lopez, Ebene R Haycroft, Amy Adair, Francesca L Mordant, Matthew T O'Neill, Phillip Pymm, Samuel J Redmond, Wen Shi Lee, Nicholas A Gherardin, Adam K Wheatley, Jennifer A Juno, Kevin J Selva, Samantha K Davis, Samantha L Grimley, Leigh Harty, Damian FJ Purcell, Kanta Subbarao, Dale Godfrey, Stephen J Kent, Wai-Hong Tham Show all



The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing antibodies and one of the most rapidly evolving domains, which can result in the emergence of immune escape mutations, limiting the effectiveness of vaccines and antibody therapeutics. To facilitate surveillance, we developed a rapid, high-throughput, multiplex assay able to assess the inhibitory response of antibodies to 24 RBD natural variants simultaneously. We demonstrate how this assay can be implemented as a rapid surrogate assay for functional cell-based serological methods to measure the SARS-CoV-2 neutralizing capacity of antibodies at the angiotensin-converting enzyme 2-RBD (ACE2-RBD) interfac..

View full abstract


Awarded by Victorian Government and Medical Research Future Fund

Awarded by National Health and Medical Research Council (NHMRC) fellowships

Funding Acknowledgements

We would thank Kathleen Wragg, Robyn Esterbauer, Helen E. Kent, and Thakshila Amarasena (The Univer-sity of Melbourne) for their assistance. This study was supported by the Victorian Government and Medical Research Future Fund GNT2002073 (to WHT, DIG, AWC, SJK, and AKW) , Emergent Ventures Fast Grant (to AWC) , and Paul Ramsay Foundation (to DIG, SJK, AKW, and AWC) . DIG, WHT, SJK, AKW, and AWC are supported by National Health and Medical Research Council (NHMRC) fellowships. WHT is a HowardHughes Medical Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z) . This work was also supported in part by funding from the Jack Ma Foundation (to DIG, DFJP, AKW, KS, and AWC) and the A2 Milk Company (to KS) . KS is supported by an NHMRC Investigator grant. NAG is supported by an Australian Research Council Discovery Early Career Researcher Award fellowship. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The authors acknowledge the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Institutes Infrastructure Support Scheme.